Claims
- 1. A taxane having the formula ##STR145## wherein X.sub.1 is --OX.sub.6, --SX.sub.7, or --NX.sub.8 X.sub.9 ;
- X.sub.2 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
- X.sub.3 and X.sub.4 are independently hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;
- X.sub.5 is --COOX.sub.10 ;
- X.sub.6 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;
- X.sub.7 is substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or sulfhydryl protecting group;
- X.sub.8 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;
- X.sub.9 is an amino protecting group;
- X.sub.10 is substituted or unsubstituted alkyl, alkenyl or aryl;
- R.sub.1 is hydroxy, protected hydroxy or together with R.sub.14 forms a carbonate;
- R.sub.2 is hydrogen, hydroxy, --OCOR.sub.31, or together with R.sub.2a forms an oxo;
- R.sub.2a is hydrogen or taken together with R.sub.2 forms an oxo;
- R.sub.4 is hydrogen, or together with R.sub.4a forms an oxo, oxirane or methylene;
- R.sub.4a is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or cyano, hydroxy, --OCOR.sub.30, or together with R.sub.4 forms an oxo, oxirane or methylene;
- R.sub.5 is hydrogen or together with R.sub.5a forms an oxo;
- R.sub.5a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R.sub.5 forms an oxo;
- R.sub.6 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or hydroxy, protected hydroxy or together with R.sub.6a forms an oxo;
- R.sub.6a is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or hydroxy, protected hydroxy or together with R.sub.6a forms an oxo;
- R.sub.7 is hydrogen or together with R.sub.7a forms an oxo;
- R.sub.7a is hydrogen, halogen, protected hydroxy, --OR.sub.28, or together with R.sub.7 forms an oxo;
- R.sub.9 is hydrogen or together with R.sub.9a forms an oxo;
- R.sub.9a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R.sub.9 forms an oxo;
- R.sub.10 is hydrogen or together with R.sub.10a forms an oxo;
- R.sub.10a is hydrogen, --OCOR.sub.29, hydroxy, or protected hydroxy, or together with R.sub.10 forms an oxo;
- R.sub.14 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or hydroxy, protected hydroxy or together with R.sub.1 forms a carbonate;
- R.sub.14a is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
- R.sub.28 is hydrogen, acyl, hydroxy protecting group or a functional group which increases the solubility of the taxane derivative; and
- R.sub.29, R.sub.30, and R.sub.31 are independently hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl.
- 2. A pharmaceutical composition which contains the taxane [derivative] of claim 1 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.
- 3. The taxane of claim 1 wherein X.sub.10 is alkenyl or aryl.
- 4. The taxane of claim 1 wherein X.sub.10 is allyl, crotyl, or benzyl.
- 5. The taxane of claim 1 wherein X.sub.10 is alkyl.
- 6. The taxane of claim 1 wherein X.sub.10 is methyl, ethyl, cyclopropyl, iso- or n-propyl, cyclohexyl, 1,3-diethoxy-2-propyl, 2-methoxy-ethyl, amyl, neopentyl, n-butyl, iso-butyl or tert-butyl.
- 7. The taxane of claim 1 wherein R.sub.1 is hydroxy.
- 8. The taxane of claim 1 wherein R.sub.2 is benzoyloxy, and R.sub.2a is hydrogen.
- 9. The taxane of claim 1 wherein R.sub.4a is acetoxy.
- 10. The taxane of claim 1 wherein R. and R.sub.6a are hydrogen.
- 11. The taxane of claim 1 wherein R.sub.7 is hydrogen, and R.sub.7a is hydroxy or protected hydroxy.
- 12. The taxane of claim 1 wherein R.sub.9a together with R.sub.9 forms an oxo.
- 13. The taxane of claim 1 wherein R.sub.10 is hydrogen; and R.sub.10a is acetoxy, hydroxy, or protected hydroxy.
- 14. The taxane of claim 1 wherein R.sub.14 and R.sub.14a are hydrogen.
- 15. The taxane of claim 1 wherein X.sub.1 is --OX.sub.6 ; X.sub.2 is hydrogen or alkyl; X.sub.4 is hydrogen; and X.sub.6 is hydrogen or hydroxy protecting group.
- 16. The taxane of claim 1 wherein
- R.sub.1 is hydroxy;
- R.sub.2a is hydrogen, and R.sub.2 is --OCOR.sub.31 ;
- R.sub.4a is --OCOR.sub.30 ;
- R.sub.6 and R.sub.6a are hydrogen;
- R.sub.7 is hydrogen, and R.sub.7a is hydroxy or protected hydroxy;
- R.sub.9a together with R.sub.9 forms an oxo;
- R.sub.10 is hydrogen, and R.sub.10a is --OCOR.sub.29, hydroxy, or protected hydroxy;
- R.sub.14 and R.sub.14a are hydrogen;
- R.sub.29 and R.sub.30 are independently substituted or unsubstituted alkyl; and
- R.sub.31 is substituted or unsubstituted monocyclic aryl.
- 17. The taxane of claim 15 wherein
- R.sub.1 is hydroxy;
- R.sub.2a is hydrogen, and R.sub.2 is --OCOR.sub.31,
- R.sub.4a is --OCOR.sub.30 ;
- R.sub.6 and R.sub.6a are hydrogen;
- R.sub.7 is hydrogen, and R.sub.7a is hydroxy or protected hydroxy;
- R.sub.9a together with R.sub.9 forms an oxo;
- R.sub.10 is hydrogen, and R.sub.10a is --OCOR.sub.29, hydroxy, or protected hydroxy;
- R.sub.14 and R.sub.14a are hydrogen;
- R.sub.29 and R.sub.30 are independently substituted or unsubstituted alkyl; and
- R.sub.31 is substituted or unsubstituted monocyclic aryl.
- 18. The taxane of claim 17 wherein R.sub.2 is benzoyloxy.
- 19. The taxane of claim 17 wherein R.sub.4a and R.sub.29 are acetoxy.
- 20. The taxane of claim 1 wherein R.sub.1 together with R.sub.14 forms a carbonate.
- 21. The taxane of claim 1 wherein R.sub.31 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, or monocyclic heteroaryl.
- 22. The taxane of claim 1 wherein R.sub.30 is hydrogen, or substituted or unsubstituted alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl.
- 23. The taxane of claim 1 wherein R.sub.7 is hydrogen or together with R.sub.7a forms an oxo; R.sub.7a is hydrogen, halogen, --OR.sub.28, or together with R.sub.7 forms an oxo; and R.sub.28 is acyl or a functional group which increases the solubility of the taxane derivative.
- 24. The taxane of claim 1 wherein R.sub.9 is hydrogen, and R.sub.9a is hydrogen, hydroxy, protected hydroxy, or acyloxy.
- 25. The taxane of claim 1 wherein R.sub.10 is hydrogen or together with R.sub.10a forms an oxo; and R.sub.10a is hydrogen or together with R.sub.10 forms an oxo.
- 26. The taxane of claim 1 wherein R.sub.14 is substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R.sub.1 forms a carbonate.
- 27. A taxane having the formula ##STR146## wherein X.sub.1 is --X.sub.6, --SX.sub.7, or --NX.sub.8 X.sub.9 ;
- X.sub.2 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
- X.sub.3 and X.sub.4 are independently hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;
- X.sub.5 is --COOX.sub.10 ;
- X.sub.6 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or hydroxy protecting group;
- X.sub.7 is substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or sulfhydryl protecting group;
- X.sub.8 is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
- X.sub.9 is an amino protecting group;
- X.sub.10 is substituted or unsubstituted alkyl, alkenyl or aryl;
- R.sub.1 is hydroxy, protected hydroxy or together with R.sub.14 forms a carbonate;
- R.sub.2 is hydrogen, hydroxy, or --OCOR.sub.31 ;
- R.sub.2a is hydrogen;
- R.sub.4 is hydrogen, or together with R.sub.4a forms an oxo, oxirane or methylene;
- R.sub.4a is hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, or cyano, hydroxy, --OCOR.sub.30, or together with R.sub.4 forms an oxo, oxirane or methylene;
- R.sub.5 is hydrogen or together with R.sub.5a forms an OXO;
- R.sub.5a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R.sub.5 forms an oxo;
- R.sub.6 and R.sub.6a are hydrogen;
- R.sub.7 is hydrogen;
- R.sub.7a is hydrogen, halogen, protected hydroxy, or --OR.sub.28 ;
- R.sub.9 is hydrogen or together with R.sub.9a forms an Oxo;
- R.sub.9a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R.sub.9 forms an oxo;
- R.sub.10 is hydrogen or together with R.sub.10a forms an oxo;
- R.sub.10a is hydrogen, --OCOR.sub.29, hydroxy, or protected hydroxy, or together with R.sub.10 forms an oxo;
- R.sub.14 is hydrogen, hydroxy, protected hydroxy or together with R.sub.1 forms a carbonate;
- R.sub.14a is hydrogen; and
- R.sub.28 is hydrogen, acyl, or hydroxy protecting group;
- R.sub.29, R.sub.30 and R.sub.31 are independently hydrogen, or substituted or unsubstituted alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl.
- 28. The taxane of claim 27 wherein X.sub.10 is alkenyl or aryl.
- 29. The taxane of claim 27 wherein X.sub.10 is allyl, crotyl, or benzyl.
- 30. The taxane of claim 27 wherein X.sub.10 is alkyl.
- 31. The taxane of claim 27 wherein X.sub.10 is methyl, ethyl, cyclopropyl, iso- or n-propyl, cyclohexyl, 1,3-diethoxy-2-propyl, 2-methoxy-ethyl, amyl, neopentyl, n-butyl, iso-butyl or tert-butyl.
- 32. The taxane of claim 27 wherein X.sub.1 is --OX.sub.6 ; X.sub.2 is hydrogen or alkyl; X.sub.4 is hydrogen; and X.sub.6 is hydrogen or hydroxy protecting group.
- 33. The taxane of claim 1 wherein:
- R.sub.4 is hydrogen, or together with R,, forms an oxo, oxirane or methylene;
- R.sub.4 is hydrogen, hydroxy, alkyl, or together with R.sub.4 forms an oxo, oxirane or methylene;
- R.sub.5 is hydrogen;
- R.sub.5a is hydrogen, hydroxy, protected hydroxy or acyloxy; and
- R.sub.30 is as defined in claim 1.
- 34. The taxane of claim 27 wherein:
- R.sub.4 is hydrogen, or together with R.sub.4a forms an oxo, oxirane or methylene;
- R.sub.4 is hydrogen, hydroxy, alkyl, or together with R.sub.4 forms an oxo, oxirane or methylene;
- R.sub.5 is hydrogen;
- R.sub.5a is hydrogen, hydroxy, protected hydroxy or acyloxy; and
- R.sub.30 is as defined in claim 27.
REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of U.S. Ser. No. 08/461,103, filed Jun. 5, 1995 now U.S. Pat. No. 5,739,362, which is a file wrapper continuation application of U.S. Ser. No. 08/094,717 filed Jul. 20, 1993 now abandoned, which is a continuation-in-part of application of U.S. Ser. No. 08/034,247, filed Mar. 22, 1993, now U.S. Pat. No. 5,430,160, which is a continuation-in-part application of U.S. Ser. No. 07/949,107, filed Sep. 22, 1992 now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/863,849, filed Apr. 6, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/862,955, filed Apr. 3, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned. This application is also a continuation-in-part application of U.S. Ser. No. 08/034,852, filed Mar. 22, 1993, now abandoned. This application is also a continuation-in-part application of U.S. Ser. No. 07/863,198, filed Apr. 3, 1992, now U.S. Pat. No. 5,243,045.
Government Interests
This invention was made with Government support under NIH Grant #CA 42031 and NIH Grant #CA 55131 awarded by the National Institutes of Health. The Government has certain rights in the invention.
US Referenced Citations (43)
Foreign Referenced Citations (29)
Number |
Date |
Country |
9190838 |
Jun 1992 |
AUX |
9223280 |
Jan 1993 |
AUX |
9223880 |
Feb 1993 |
AUX |
9335048 |
Aug 1993 |
AUX |
9335050 |
Aug 1993 |
AUX |
9337563 |
Sep 1993 |
AUX |
9341556 |
Jan 1994 |
AUX |
9351152 |
Apr 1994 |
AUX |
9351151 |
Apr 1994 |
AUX |
9351148 |
Apr 1994 |
AUX |
9351153 |
Apr 1994 |
AUX |
9453395 |
Apr 1994 |
AUX |
9454257 |
May 1994 |
AUX |
9455659 |
Jun 1994 |
AUX |
9461446 |
Sep 1994 |
AUX |
9463971 |
Sep 1994 |
AUX |
0247378 B1 |
Dec 1987 |
EPX |
0253739 A1 |
Jan 1988 |
EPX |
0253738 A1 |
Jan 1988 |
EPX |
0336840 A1 |
Oct 1989 |
EPX |
0336841 A1 |
Oct 1989 |
EPX |
0400971 A2 |
Dec 1990 |
EPX |
0428376 A1 |
May 1991 |
EPX |
0534707 A1 |
Sep 1992 |
EPX |
0534708 A1 |
Sep 1992 |
EPX |
0534709 A1 |
Sep 1992 |
EPX |
919224 |
Nov 1993 |
ZAX |
WO 9209589 |
Jun 1992 |
WOX |
9302065 |
Mar 1993 |
WOX |
Non-Patent Literature Citations (13)
Entry |
Holton et al., "A Synthesis of Taxusin", J. Am. Chem. Soc., vol. 110, pp. 6558-6560 (1988). |
Samaranayake et al., "Modified Taxols. 5.1 Reaction of Taxol With Electrophilic Reagents and Preparation of a Rearranged Taxol Derivative with Tubulin Assembly Activity", J. Org. Chem., vol. 56, No. 17, pp. 5114-5119 (1991). |
Wani et al., "Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus Brevifolia", JACS 93:9, pp. 2325-2327 (May 5, 1971). |
Holton, "Synthesis of the Taxane Ring System", JACS, vol. 106, pp. 5731-5732 (1984). |
Mukerjee et al., ".beta.-Lactams: Retrospect and Prospect", Tetrahedron, vol. 34, Report No. 52, pp. 1731-1767 (1978). |
Science/Technology, "New Family of Taxol, Taxotere Analogs Developed", Chem. & Engineering News, pp. 26-27 (Apr. 12, 1993). |
Senilh et al., "Chime Organique Biologique--Hemisynthese de nouveaux analogues du taxol. Etude de leur interaction avec la tubuline", C.R. Acad. Sc. Paris, Serie II, t. 299, No. 15, pp. 1039-1043 (1984). |
Ojima et al., "New and Efficient Approaches to the Semisynthesis of Taxol and Its C-13 Side-chain Analogs by Means of .beta.-Lactam Synthon Method", Tetrahedron, vol. 48, No. 34, pp. 6985-7012 (1992). |
Denis & Green, "A Highly Efficient, Practical Approach To Natural Taxol", J. Am. Chem. Soc., vol. 110, No. 17, pp. 5917-5919, (1988). |
V. Farina et al., "The Chemistry of Taxanes: Unexpected Rearrangement Of Baccatin III During Chemoselective Debenzoylation with Bu.sub.3 SnOMe/LiCl" Tetrahedron Letters, vol. 33, No. 28, pp. 3979-3982 (1992). |
D. Kingston et al., "Progress In the Chemistry of Organic Natural Products", Springer-Verlag, New York, pp. 1-206 (1993). |
G. Georg et al., "Novel Biologically Active Taxol Analogues: Baccatin III 13-(N-(p-Chlorobenzoyl)-(2'R,2'S)-3'-phenylisoserinate) and Baccatin III 13-(N-Benzoyl-(2'R,3'S)-3'-(p-chlorophenyl)isoserinate)", Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 4, pp. 295-298 (1992). |
International Search Report Issued for PCT/US93/10813, dated Mar. 11, 1994. |
Related Publications (1)
|
Number |
Date |
Country |
|
863198 |
Apr 1992 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
461103 |
Jun 1995 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
094717 |
Jul 1993 |
|
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
034247 |
Mar 1993 |
|
Parent |
949107 |
Sep 1992 |
|
Parent |
863849 |
Apr 1992 |
|
Parent |
862955 |
Apr 1992 |
|
Parent |
763805 |
Sep 1991 |
|